IVIG for PANDAS: What It Is, What the Evidence Says, and How Families Actually Get It Covered

For families considering IVIG for PANS or PANDAS, there are really two battles happening at once.

The first is medical: is this the right treatment for my child, at this point, given everything else we have tried? The second is bureaucratic, and for many families it turns out to be the harder one: will insurance actually pay for it?

Most articles about IVIG only address the first question. This one addresses both, because new peer-reviewed research has finally put numbers to what families in this community have been saying for years.

What IVIG is

IVIG stands for intravenous immunoglobulin. It is a preparation of antibodies pooled from the plasma of thousands of healthy donors, given to a patient through an IV infusion.

It is not a new or fringe treatment in general medicine. IVIG has been used for decades in a range of immune-mediated conditions. What is still being worked out is precisely how, and in whom, it should be used for PANS and PANDAS.

The working theory in PANS/PANDAS is a neuroimmune one. In susceptible children, the immune system appears to misfire after an infection, producing inflammation that affects the brain and drives the sudden onset of obsessive-compulsive symptoms, tics, anxiety, restricted eating, and dramatic behavioral change. IVIG is one of several immunomodulatory approaches aimed at that misfiring immune response rather than at the symptoms alone.

Where IVIG sits in the treatment sequence

This is the part families most often misunderstand, so it is worth being precise.

IVIG is not a first step. Expert guidance generally describes a staged approach: treat any underlying infection, address the immune and inflammatory response when appropriate, and support the child's mental health with therapy and, when needed, medication. IVIG sits in that middle category, and it is typically considered for children with more significant or persistent illness rather than as an opening move.

The National Institute of Mental Health notes that more aggressive immunomodulatory options such as IVIG carry side effects and risks, and describes them as being considered for severe cases. That framing matters. IVIG is a serious intervention, not a routine one.

A recent academic review from the Immunoglobulin National Society put the decision-making question well:

"Shared decision-making is central to treatment sequencing, particularly when considering immunomodulatory therapies such as IVIG. Families should be counseled regarding the evolving evidence base, potential benefits and risks, and the possibility that multiple treatment cycles may be necessary in persistent or relapsing disease."

Three honest things are packed into that sentence, and families deserve to hear all three:

• The evidence base is evolving, not settled.

• There are real risks and side effects, not just benefits.

• One round may not be enough. In persistent or relapsing illness, multiple cycles may be needed.

A doctor who tells you IVIG is a guaranteed cure is overselling it. A doctor who tells you it never helps anyone is ignoring the families who have watched their child come back. The truthful answer lives in between, and it is why the decision has to be made carefully, with a doctor who knows your child.

The part nobody prepares you for: insurance

Here is where the conversation usually breaks down. A family and their physician agree that IVIG is medically appropriate, and then the process stalls for months inside an insurance company.

Until recently, that experience was mostly anecdotal. Now there is peer-reviewed evidence. The Brain Inflammation Collaborative published an open-access study surveying 60 caregivers and adult PANS patients who sought IVIG treatment. The findings are stark:

Approval is the exception, not the rule.

• Only 12% received insurance approval without having to file an appeal.

• Many families faced repeated denials before eventually obtaining coverage.

• Patients with PANS alone waited significantly longer to begin treatment than patients with conditions where IVIG is more routinely covered.

The financial damage is real.

Among families without adequate coverage:

• 58% borrowed money to pay for treatment.

• 21% sold major assets.

• Roughly one-third reported extreme financial stress.

And yet the treatment mattered.

Patients reported substantial improvements in quality of life in the six months following IVIG, and caregivers reported meaningful improvements in family quality of life.

Read that combination again, because it is the whole problem in two lines: the treatment helped, and families had to borrow money and sell assets to get it.

What this means practically for your family

If IVIG is on the table for your child, plan for the administrative fight as deliberately as you plan for the medical one. In our experience, the families who get through it fastest are the ones whose documentation is airtight before the first submission.

That usually means:

• A precise symptom-onset timeline. When did the change begin, how abruptly, and what did it look like. Vague histories get denied.

• The full treatment record. Everything tried, in what order, for how long, and how your child responded. Insurers want to see that less aggressive options were attempted first.

• Relevant lab and infection history, including strep testing and any other documented triggers.

• Functional impact. School attendance, ability to eat, ability to leave the house. Denials often hinge on the insurer not understanding how disabling the illness actually is.

• A letter of medical necessity from a physician who genuinely knows the condition.

• The expectation that you may need to appeal. Given that only 12% were approved without one, an appeal is closer to the normal path than a worst case. Plan for it rather than being blindsided by it.

Peer-reviewed data can help here too. A published study documenting systematic access barriers is a legitimate thing to cite in an appeal, and it is part of why research like this matters beyond the academic world.

A note from Dr. Adame

I want to be honest about what this looks like from inside a clinic.

This month, one of our patients was approved in a couple of weeks, with no denial and no appeal. I almost cried. My team almost cried. I genuinely cannot remember the last time that happened.

That reaction tells you everything about how abnormal a smooth approval is. Fighting insurance companies on behalf of children who are visibly suffering is demoralizing work, and it was taking a real toll on my staff. So we have brought in dedicated, US-based prior-authorization support to carry that load, specifically so that no family gets left hanging while we are stuck on hold. From the patient side, nothing changes except that someone is always on it.

I did not want to hand that off. But my team needed the relief, and our families needed the process to keep moving. Both things were true.

How families can help change this

The reason we now have hard numbers on IVIG denials is that families took the time to report their experiences. That data is the strongest tool this community has for pushing insurers and policymakers toward better coverage.

Researchers are currently collecting real-world treatment data through the unhide® platform's PANS/PANDAS Medication Questionnaire, looking at which interventions are actually moving the needle across thousands of families rather than in small clinical snapshots. If you have been through this, contributing your history is one of the most concrete advocacy actions available to you.

Where we fit

At Culver Pediatrics Center, Dr. Noemi Adame runs a dedicated PANS/PANDAS clinic in Culver, Indiana, combining conventional medical treatment with holistic support. For families who cannot travel, a doctor-to-doctor virtual consultation provides a records review, an extended consult, and a written plan your local physician can implement.

If you are weighing IVIG, the first step is a conversation with a doctor who understands both the medicine and the maze around it.

This article is for general educational purposes and is not a substitute for medical advice. IVIG carries potential risks and side effects and is not appropriate for every child. Treatment decisions should be made with a qualified physician who knows your child's history.